312 related articles for article (PubMed ID: 29407881)
1. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
[TBL] [Abstract][Full Text] [Related]
2. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
[TBL] [Abstract][Full Text] [Related]
3. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
[TBL] [Abstract][Full Text] [Related]
4. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
Fernández-Laso V; Méndez-Barbero N; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of vascular calcification and mortality in patients with ESRD.
Scialla JJ; Kao WH; Crainiceanu C; Sozio SM; Oberai PC; Shafi T; Coresh J; Powe NR; Plantinga LC; Jaar BG; Parekh RS
Clin J Am Soc Nephrol; 2014 Apr; 9(4):745-55. PubMed ID: 24458076
[TBL] [Abstract][Full Text] [Related]
6. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?
Gungor O; Kircelli F; Asci G; Carrero JJ; Tatar E; Demirci MS; Ozbek SS; Ceylan N; Toz H; Ozkahya M; Ok E
J Nephrol; 2013; 26(1):136-43. PubMed ID: 22505251
[TBL] [Abstract][Full Text] [Related]
7. Vascular calcification in patients with nondialysis CKD over 3 years.
Górriz JL; Molina P; Cerverón MJ; Vila R; Bover J; Nieto J; Barril G; Martínez-Castelao A; Fernández E; Escudero V; Piñera C; Adragao T; Navarro-Gonzalez JF; Molinero LM; Castro-Alonso C; Pallardó LM; Jamal SA
Clin J Am Soc Nephrol; 2015 Apr; 10(4):654-66. PubMed ID: 25770175
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis.
Ramirez-Sandoval JC; Casanova I; Villar A; Gomez FE; Cruz C; Correa-Rotter R
Perit Dial Int; 2016; 36(3):262-8. PubMed ID: 26293840
[TBL] [Abstract][Full Text] [Related]
9. Vascular calcification biomarkers and peripheral arterial disease.
Kapetanios D; Karkos C; Giagtzidis I; Papazoglou K; Kiroplastis K; Spyridis C
Int Angiol; 2016 Oct; 35(5):455-9. PubMed ID: 26044839
[TBL] [Abstract][Full Text] [Related]
10. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.
Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM
Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348
[TBL] [Abstract][Full Text] [Related]
12. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
[TBL] [Abstract][Full Text] [Related]
14. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
15. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study.
Chae SY; Chung W; Kim YH; Oh YK; Lee J; Choi KH; Ahn C; Kim YS
J Korean Med Sci; 2018 Dec; 33(53):e322. PubMed ID: 30595681
[TBL] [Abstract][Full Text] [Related]
16. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.
Tousoulis D; Siasos G; Maniatis K; Oikonomou E; Kioufis S; Zaromitidou M; Paraskevopoulos T; Michalea S; Kollia C; Miliou A; Kokkou E; Papavassiliou AG; Stefanadis C
Int J Cardiol; 2013 Sep; 167(5):1924-8. PubMed ID: 22640692
[TBL] [Abstract][Full Text] [Related]
17. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
[TBL] [Abstract][Full Text] [Related]
18. Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes.
Gregg LP; Adams-Huet B; Li X; Colbert G; Jain N; de Lemos JA; Hedayati SS
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28679558
[TBL] [Abstract][Full Text] [Related]
19. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.
Collado S; Coll E; Nicolau C; Azqueta M; Pons M; Cruzado JM; de la Torre B; Deulofeu R; Mojal S; Pascual J; Cases A
BMC Nephrol; 2017 Sep; 18(1):290. PubMed ID: 28882110
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
